About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, November 23rd, 2015

The QualityStocks
Daily Stock List


Matinas BioPharma Holdings, Inc. (MTNB)

Tiny Gems, SmallCapVoice, Stock News Now, and Stock News reported on Matinas BioPharma Holdings, Inc. (MTNB), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Established in 2011, Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It concentrates on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections. Its proprietary, disruptive technology employs lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, making them safer, more tolerable, less toxic and orally bioavailable. Matinas BioPharma Holdings has its corporate office in Bedminster, New Jersey.

The Company’s focus is on the development and commercialization of lipid-based prescription therapeutics for the treatment of infectious diseases and cardiovascular and metabolic conditions. Matinas BioPharma’s emphasis is on creating highly differentiated, safe, and efficacious therapies using its expertise in drug formulation and development to address important unmet medical needs.

Recent additions to its product pipeline, including MAT2203 and MAT2501, position the Company to become a leader in the safe and effective delivery of anti-infective therapies utilizing its proprietary lipid-crystal nano-particle cochleate formulations. Matinas intends to file an investigational new drug application (IND) for MAT2501.

The Company has its clinical development strategy for MAT2203 (its lead drug candidate), a novel lipid-crystal nano-particle orally delivered formulation of Amphotericin B for the treatment of invasive fungal infections, and MAT2501, an early-stage program to treat gram-negative bacterial infections utilizing an orally available formulation of Amikacin, a broad spectrum aminoglycoside.

Matinas BioPharma has its investigational drug MAT9001. This is a proprietary prescription-only omega-3 fatty acid-based composition, consisting of docosa-pentaenoic acid (DPA) and other omega-3 fatty acids, which is under development for therapeutic applications with severe hypertriglyceridemia (TG>500 mg/dL) as the lead indication. Matinas BioPharma has purposely designed MAT9001 to provide a differentiated pharmacotherapy for the treatment of dyslipidemia. It is exploring development and partnership options for MAT9001.

Recent corporate achievements for Matinas BioPharma include receiving a Notice of Allowance of U.S. patent for encochleated siRNA, providing a pathway to the development of orally administered RNA based therapies. Furthermore, the Company presented key data on the pharmacokinetics and efficacy of encochleated atovaquone in a murine model of pneumocystis, providing more evidence for significant tissue penetration with oral administration, at IDWEEK2015.

Matinas BioPharma Holdings, Inc. (MTNB), closed Monday's trading session at $0.91, up 26.37%, on 90,398 volume with 16 trades. The average volume for the last 60 days is 15,479 and the stock's 52-week low/high is $0.3101/$1.46.

Premier Biomedical, Inc. (BIEI)

Innovative Marketing, SmallCapVoice, PennyStocks24, Information Solutions Group, and FeedBlitz reported on Premier Biomedical, Inc. (BIEI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Premier Biomedical, Inc. is a research-based medical development company. Its aim is to discover and develop medical treatments, in collaboration with the University of Texas at El Paso (UTEP) and the US Department of Defense, specifically targeting the treatment of Alzheimer's Disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease), Blood Sepsis and Viremia, and Cancer. Premier Biomedical is based in El Paso, Texas.

The Company has licensed the technology behind numerous provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Premier Biomedical has developed a determined timetable to further the development of these technologies via the laboratory, hospital, and clinical trials. It has commenced the development of potential patient trial application lists.

It is initially targeting the treatment of Alzheimer's disease, Traumatic Brain Injury, and Cancer. Premier announced in June of 2014 that the United States Patent Office approved a patent on its proprietary medication Feldetrex ™. The design of this medication is to relieve the symptoms of neuropathic pain and fibromyalgia.

Premier Biomedical has been evaluating strategies to take its own Anti-CTLA4 breast cancer treatment through the Food and Drug Administration (FDA) approval process. Premier has a number of other ongoing projects, in addition to its Anti-CTLA-4-based breast cancer drug. In two upcoming clinical trials, the Company’s plan is to test its Feldetrex™ pain medication, followed by a separate clinical trial of its core technology designed to remove the pathophysiological basis of the disease.

Premier Biomedical has signed a Patent License Agreement with UTEP, covering the cancer treatment process called "CD152-LDMC" that the two entities have been developing in cooperation at the Border Biomedical Research Center, located in UTEP's $45-million Bioscience Research Building. The proprietary process strives to block a molecule called cytotoxic T-lymphocyte antigen or CTLA-4, through combining CTLA-4 blocking antibody CD152, along with Low Dose Metronomic Chemotherapy. Important progress has been made over the past year advancing the development of CD152-LDMC.

Last week, Premier Biomedical announced it has obtained exclusive rights to the recently allowed U.S. patent application, "Sequential Extracorporeal Treatment of Bodily Fluids", covering the basic technology supporting the Company’s continuing research into new, inventive treatments for many of today's most debilitating diseases. Premier’s intention is to develop its proprietary methodology in which the pathologies are eradicated by sequentially dialyzing the patient's blood extracorporeally (outside the body). This method will use designer antibodies to physically remove the pathophysiologic basis of the disease.

Premier Biomedical, Inc. (BIEI), closed Monday's trading session at $0.0155, down 2.52%, on 5,577,134 volume with 218 trades. The average volume for the last 60 days is 4,262,445 and the stock's 52-week low/high is $0.0023/$0.225.

Yew Bio-Pharm Group, Inc. (YEWB)

Greenbackers reported previously on Yew Bio-Pharm Group, Inc. (YEWB), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Founded in 1996, Yew Bio-Pharm Group, Inc., through its operating entity, Harbin Yew Science and Technology Development Co., Ltd. (HDS), is a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine (TCM), and products made from yew timber in China. The Company has its headquarters in Xiangfang District, Harbin City, Heilongjiang Province, China. Yew Bio-Pharm Group’s shares trade on the OTC Bulletin Board.

Raw material from the species of yew tree that Yew Bio-Pharm grows contains taxol, and TCM containing yew raw materials has received approval as a traditional Chinese medicine in China for the secondary treatment of certain cancers. Yew Bio-Pharm grows Japanese yew trees (also known in China as Northeast yew trees), taxus cuspidata, on mountain hillsides near Harbin. It cultivates them in four nurseries it operates close to Harbin.

The Company employs a patented, accelerated growth technology to hasten the growth and maturity and commercialization of yew trees. In addition, Yew Bio-Pharm operates production facilities to manufacture yew handicrafts.

Yew Bio-Pharm’s patented Asexual Reproduction Method hastens the commercial viability of a yew tree. Therefore, a yew tree can be utilized for commercialization starting in around three years, in comparison to more than 50 years for naturally grown yew trees. Via this method, the Company can more than replenish the number of yew trees it cultivates and puts into production. The Patent is valid through September 29, 2030. The patented Asexual Reproduction Method was developed by Yew Bio-Pharm’s Founder and President, Mr. Zhiguo Wang.

Moreover, Yew Bio-Pharm Group also recently formed a division to concentrate on organic foods and dietary supplements with the goal of developing new business opportunities in related industries.

Last week, Yew Bio-Pharm Group reported financial results for the three- and nine-months ended September 30, 2015. Total revenues for Q3 of 2015 rose 194 percent to $5.0 million from $1.7 million the year prior. For Q3 2015, gross profit was $1.4 million, or 28.4 percent of total revenues, versus $1.4 million, or 82.7 percent of total revenues for the comparable 2014 quarter. The decrease in the gross profit margin was chiefly because of the lower gross margin yield of TCM raw materials and handicrafts. Net income for the three months ended September 30, 2015 increased 4.6 percent to $933,514 from $892,716 in the same quarter in 2014.

Yew Bio-Pharm Group, Inc. (YEWB), closed Monday's trading session at $0.11, even for the day. The average volume for the last 60 days is 7,724 and the stock's 52-week low/high is $0.085/$0.47.

ALR Technologies, Inc. (ALRT)

Top Penny Stocks Movers, PennyStocks24, Information Solutions Group, SMS Penny Picks, AwesomeStocks, OtcShort Report, 007 Stock Chat, and PennyStockSpy reported earlier on ALR Technologies, Inc. (ALRT), and we are highlighting the Company as well, here at the QualityStocks Daily Newsletter.

Founded in 1998, ALR Technologies, Inc. is a medical device company providing remote monitoring and care facilitation for patients with chronic diseases. It has developed the Food and Drug Administration (FDA)-cleared and Health Insurance Portability and Accountability Act (HIPAA) compliant Health-e-Connect System, which collects data from blood glucose meters and uploads to a secure website. ALR Technologies is headquartered in Richmond, Virginia.

Trained Facilitators use the Health-e-Connect System to achieve efficiency of care among patients, clinicians and caregivers to improve outcomes and assist health plans to optimize their quality goals. Currently, ALR Technologies is focusing on diabetes. The Company will expand its services to cover other chronic diseases anchored on verifiable data.

Health-e-Connect evolved from ALR Technologies’ earlier product offerings also designed to help a patient in meeting the objectives in their Care Plan. ALR Technologies’ system goal is to assist patients to adhere to their care plan, improving the quality of diabetes care and making such care more cost effective to providers.

Last week, ALR Technologies announced that a 10-month pilot of the ALRT remote monitoring system for diabetes by the Kansas City Metropolitan Physician Association (KCMPA) found considerable improvement in glycemic control for those patients who used the system versus those who dropped out of the pilot. Patients taking part in the pilot program of the ALRT system experienced an average A1C reduction of 1.22 percent. Patients who dropped from the program before the three-month threshold saw A1C levels rise by +0.66 percent.

The ALRT system, developed by ALR Technologies, underwent testing in KCMPA-affiliated clinics across the Greater Kansas City area as a diabetes management element of KCMPA's Quality Improvement Plan designed to decrease A1C scores for some of their most challenging patients. The pilot was so successful that one participating clinic chose to pay for the ALRT program for its patients before the final results were tabulated.

ALR Technologies, Inc. (ALRT), closed Monday's trading session at $0.006, even for the day, on 130,000 volume with 3 trades. The average volume for the last 60 days is 56,929 and the stock's 52-week low/high is $0.0031/$0.028.

Jammin Java Corp. (JAMN)

PennyStocks24, WallstreetsHotteststocks, Wallstreetbuzz, SmallCapVoice, and Stock News Now reported earlier on Jammin Java Corp. (JAMN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Jammin Java Corp., d/b/a Marley Coffee, is a provider of premium, artisan roasted coffee. The Company supplies this to the grocery, retail, online, service, hospitality, office coffee service, and the big box store industry. It continues to develop its coffee lines under the Marley Coffee brand, under its exclusive licensing agreement with 56 Hope Road. The Marley Coffee estate farm is 52 acres. The farm sits upon the Jamaican Blue Mountains, in Chepstowe, Portland, Jamaica.  Jammin Java is based in Denver, Colorado.

Marley Coffee® was founded by Rohan Marley, the son of musician Bob Marley [Robert Nesta Marley O.M.]. Marley Coffee is a sustainably grown, ethically farmed and artisan-roasted gourmet coffee company. Marley Coffee sources coffee beans from around the world. This includes Ethiopia, Central and South America, and Jamaica.

Jamaica Blue Mountain® coffee is believed by many connoisseurs to be the world’s finest. It has a reputation for its delicate balance of floral aroma, acidity and full body. The rare bean is grown in the hills of the Jamaican Blue Mountains that rise from elevations of 3,000 to 7,500 feet.

Each Marley Coffee bean is at least one of the following: Organic, Jamaica Blue Mountain®, Rainforest Alliance Certified™, Swiss Water® Process Decaf or Kosher. Marley Coffee has signed an agreement with Bevyz to produce Marley Coffee hot, cold and sparkling capsules for the Bevyz system. Bevyz is a proprietary, single-serve drink system. It dispenses hot, cold and sparkling beverages using its unique capsule technology.

Marley Coffee is offering its new recyclable EcoCup. This is an easy-to-recycle single-serve capsule that is compatible with most Keurig® K-Cup® machines. The recyclable EcoCup directly addresses consumer frustration with a lack of recyclable options in the single-serve capsule arena. The recyclable EcoCup is a clear capsule. It allows consumers to see the coffee grounds and the filter through the capsule exterior while also preventing oxidation.

Recently, Marley Coffee announced new distribution with Acme Markets, Inc. This company is a 107-store chain based in the Delaware Valley metropolitan area. It has locations across Philadelphia, Pennsylvania, New Jersey, Delaware and Maryland. Acme Markets will carry four types of Marley Coffee roasts in both 8oz bags and RealCup® single serve capsules.

Jammin Java Corp. (JAMN), closed Monday's trading session at $0.1361, down 7.73%, on 70,195 volume with 27 trades. The average volume for the last 60 days is 231,868 and the stock's 52-week low/high is $0.0575/$0.31.


The QualityStocks
Company Corner


Hemp, Inc. (HEMP)

The QualityStocks Daily Newsletter would like to spotlight Hemp, Inc. (HEMP). Today, Hemp, Inc. closed trading at $0.056, up 1.82%, on 4,808,606 volume with 222 trades. The stock’s average daily volume over the past 60 days is 3,505,618, and its 52-week low/high is $0.039/$1.00.

Hemp, Inc. announced today that sales for the 3rd quarter ending September 30, 2015 increased 53.8% over the 2nd quarter. Bruce Perlowin, CEO of Hemp, Inc., stated, "The industrial hemp industry is really booming. More states are beginning to realize it is more advantageous for them to legalize it. As you know, North Carolina, home to our industrial hemp commercial decortication facility, legalized hemp. Farmers in North Carolina now have the option to cultivate hemp crops with easy access to Hemp, Inc.'s multipurpose industrial hemp commercial processing facility."

Hemp, Inc. (HEMP) is engaged in the research and development of all things made of industrial hemp. From fabric, paper, cosmetics, food and jewelry to pulp, fuel, paints and more, the application of hemp represents a myriad of possibilities. The company strategizes to recognize the profits that could be made in making the world a better place through the industrial commercialization of this resource.

Hemp, Inc. subsidiaries include Industrial Hemp Manufacturing, LLC, which will soon be offering DrillWall™ for maintaining the seals on drilling for water, oil, gas and any other liquid or gas; and The Industrial Hemp and Medical Marijuana Consulting Company, Inc., which pulls pertinent market information from a vast network of professionals, specialists and experts from various niches of the hemp industry.

Las Vegas-based Hemp, Inc. conducts its operations through its 70,000-square-foot processing plant and decortication line of equipment, which is useful manufacturing more than 50,000 commercial products. The company's current line of offerings include hemp-infused body candles, shampoo and conditioner, smoothies, jewelry, healing oils, twine, lip balm and skin moisturizers.

Hemp products are used all over America every day and are sold in the largest and most respected stores. Not to be confused with marijuana, hemp does not contain psychoactive compounds and is legal in the United States and most of the world. Hemp, Inc.'s mission is to educate the public on this important differentiation while working to expand corporate infrastructure and invest in profitable, legal and diversified ventures poised to bring reward and value to shareholders. Disclaimer

Hemp, Inc. Company Blog

Hemp, Inc. News:

Hemp, Inc. Reports 3rd Quarter 2015 Financial Results as the Industry Continues to Boom

U.S. Hemp Fiber Sale Agreement Announced by Hemp, Inc.

Trader's Choice Releases New Research Update on Hemp, Inc.

GTX Corp. (GTXO)

The QualityStocks Daily Newsletter would like to spotlight GTX Corp. (GTXO). Today, GTX Corp. closed trading at $0.0115, off by 3.36%, on 63,447 volume with 5 trades. The stock’s average daily volume over the past 60 days is 652,797, and its 52-week low/high is $0.0058/$0.023.

GTX Corp. today announced the availability of a new audio interview with Patrick Bertagna, CEO of GTX Corp (OTCQB: GTXO), an IoT platform and leading provider of personal location GPS wearable technology and wandering assistive technology. The interview can be heard at http://www.QualityStocks.net/interview-gtxo.php.

GTX Corp. (GTXO), through its robust IoT enterprise monitoring platform and licensing, subscription recurring revenue business model, offers a complete end-to-end solution backed by an extensive portfolio of patents with filing dates going back as early as 2002, patents pending, registered trademarks, copy rights and URLs. GTX was featured in a 38-page research piece outlining the value proposition of the company's IP portfolio, and was also published in a SeeThruEquity research report discussing the value of the company's IP.

GTX has established a growing global distribution network with partners in more than 20 countries, and has garnered millions of dollars' worth of free media with coverage on CNN, Good Morning America, The Doctors, Fox News, Discovery Channel, ABC, NBC, CBS, The New York Times, LA Times, U.S.A. Today, the LA Business Journal, AARP and hundreds of other television, radio, magazine and newspaper media outlets across the globe.

The company's flagship, patented GPS SmartSoles were recently showcased in Munich at the Telefonica Digital Innovation Day 2015; was featured in AARP's 2015 technology gear guide; and came in second place, with Microsoft finishing first and Samsung taking third, in the 2015 Wearables, Health, Fitness & Wellness category at CTIA's Hot for the Holidays Awards competition.

As GTX continues to expand its brand awareness and distribution channels both domestically and internationally, in parallel it also plans to introduce new products with an emphasis on e-health and wellness. Corporate strategies are guided by a visionary management team with the insight and experience needed to navigate the plentiful opportunities and potential market share in the emerging multibillion IoT and Wearable Tech industries.

"With approximately 2% of the population having been diagnosed with Alzheimer's, dementia, autism, TBI or some other cognitive disorder which may lead to wandering due to memory loss, GTX plays a vital role in the safety, security and recovery of these individuals and their caregivers." --- Patrick Bertagna GTX Corp CEO. Disclaimer

GTX Corp. Company Blog

GTX Corp. News:

GTX Corp (GTXO) CEO Featured in Exclusive QualityStocks Interview

GTX Corp Reports Third Quarter 2015 Financial Results and Business Overview

GTX Corp (GTXO) Announces Engagement of QualityStocks Investor Relations Services

Moxian, Inc. (MOXC)

The QualityStocks Daily Newsletter would like to spotlight Moxian, Inc. (MOXC). Today, Moxian, Inc. closed trading at $5.00, even for the day. The stock’s average daily volume over the past 60 days is 686, and its 52-week low/high is $5.00/$6.50.

Moxian, Inc. announced the online availability of its interview with Mr. Edmund Ooi, Vice President and Director of Creative & Marketing for Moxian, Inc. (OTCQB: MOXC). The full audio interview is available at http://MOXC.MissionIR.com/interview.html.

Moxian, Inc. (MOXC) engages in the business of providing social marketing and promotion platforms designed to help merchants accelerate and advertise their business growth through social media. These products and services enable merchants to run targeted advertising campaigns and promotions, and aim to enhance the interaction between users and merchant clients by using consumer behavior data compiled from the Moxian database of user activities. The company has two primary core products: Moxian+ User App and Moxian+ Business App.

Developed in Shenzhen, China, Moxian integrates social media, entertainment and business intelligence. The Multi-Channel Social Commerce Platform, which includes a variety of tools such as Moxian's proprietary Social Customer Relationship Management (SCRM) system, generates knowledgeable data for merchants. This way, consumers and businesses are able to connect and interact with one another to achieve the concept of "online lifestyle, offline fun."

Moxian+ User App serves as an App driven for consumer users to use the platform, consisting of our proprietary virtual currency (MO-Coin and MO-Points), social networking, redemption centre and game centre. Users can earn MO-Coins by playing games, and then use those coins to redeem prizes sponsored by Moxian and client merchants. This model not only drives registered consumers to Moxian and merchant, but also provides merchants the opportunity to advertise, run marketing campaigns, and learn about their customers through the Platform.

Moxian+ Business App is an independent App with built in Social Customer Relationship Management tool built for merchants. Merchants are able to set up a store on the Moxian platform through this business App, push promotions via a variety of methods offered on the platform and look at generated report customized to their own shop.

Moxian's management team has more than 100 years of combined experience in a variety of pertinent endeavors, including management of private and public enterprise, multi-national organizations, quality, engineering and procurement, finance, marketing, communication and more. Together, Moxian's management team is effecting the company's aim to create and lead a personalized social network platform that best fits users and businesses. Disclaimer

Moxian, Inc. Company Blog

Moxian, Inc. News:

MissionIR Exclusive Audio Interview With Moxian, Inc. (MOXC) Creative & Marketing VP Edmund Ooi

Moxian, Inc. (MOXC) Announces Engagement of DreamTeamNetwork Corporate Communications Service Suite

Moxian Announces China New Media Integrated Development Conference Sponsorship Agreement Has Changed

Giggles N' Hugs, Inc. (GIGL)

The QualityStocks Daily Newsletter would like to spotlight Giggles N' Hugs, Inc. (GIGL). Today, Giggles N' Hugs, Inc. closed trading at $0.169, up 12.74%, on 3,330 volume with 6 trades. The stock’s average daily volume over the past 60 days is 29,075, and its 52-week low/high is $0.101/$0.55.

Los Angeles-based Giggles N' Hugs, Inc. (GIGL) is a first-of-its-kind, award-winning family restaurant and play space that combines organic gourmet food with the play elements for children in a 2500-square-foot play space in the middle of the restaurant. The concept is similar to Chuck E. Cheese, but offers a unique healthier, high-end version for health conscious parents and families. Parents eat and relax while the kids have an incredible time playing in the custom-made play area with giant climbers, dragons, castles, pirate ships slides and swings and a multitude of other toys.

In addition to nightly shows and concerts, every 30 minutes Giggles N' Hugs provides an activity such as face painting, disco dance parties, karaoke, games, arts and crafts, and much more. Giggles N' Hugs has been voted the No. 1 family restaurant, No. 1 birthday party place, and the No. 1 indoor play space in all of Los Angeles, and has attracted a star-studded list of customers including Sandra Bullock, Heidi Klum, Jessica Alba, Halle Berry, Jennifer Garner and Ben Affleck, Denis Quaid, Mark Whalberg, Adam Sandler, Dustin Hoffman and many more.

Revenue is derived from several sources, including food and beverage sales, beer and wine, birthday parties (40%), admission and membership fees to play, along with retail sales. These revenue-generating locations are also highly sought-after tenants. The company currently has three locations in the top premier malls around Los Angeles; four of the largest mall owners in the country are giving Giggles N' Hugs up to 75% discounts on rent and providing upward of $700,000 of upfront cash for each location to get Giggles N' Hugs into their malls around the country.

Growth and recognition of this caliber are driven by a very powerful management team. Giggles N' Hugs President John Kaufman was the COO at California Pizza Kitchen when the founders had just two locations. Joined by Giggles N' Hugs' CFO Phillip Gay, who at the time was CFO of California Kitchen, Kaufman grew the company from two to more than 100 locations – at which time it was bought by Pepsi Co. Kaufman was recruited as president of Koo Koo Roo Chicken, one of the fastest growing fast-casual concepts on the west coast, while Gay joined Wolfgang Puck Restaurants group as CFO, eventually becoming the CEO.

Giggles N' Hugs was founded as a truly "kid friendly" establishment catered specifically to the size, interests, and nutrition needs of children. Since opening its first Giggles N' Hugs in 2009, the company has received a steady stream of interest from more than 300 interested parties looking to expand the concept – via franchise or master licenses – in the U.S. as well globally in countries such as Germany, England, Dubai, Russia, Colombia, Australia , Singapore, Turkey, among the many more. Disclaimer

Giggles N' Hugs, Inc. Company Blog

Giggles N' Hugs, Inc. News:

Westfield Seeks To Expand Partnership with Giggles N Hugs

Giggles N’ Hugs Announces Second Quarter 2015 Financial Results

Giggles N’ Hugs Advances Negotiations with largest National Mall Owners

Avant Diagnostics, Inc. (AVDX)

The QualityStocks Daily Newsletter would like to spotlight Avant Diagnostics, Inc. (AVDX). Today, Avant Diagnostics, Inc. closed trading at $0.27, even for the day, on 294 volume with 3 trades. The stock’s average daily volume over the past 60 days is 2,534, and its 52-week low/high is $0.2002/$1.95.

Avant Diagnostics, Inc. (AVDX) is a medical diagnostic technology company that specializes in large panel biomarker screening. The company's first test, OvaDx®, is a sophisticated microarray-based test designed to detect pre-symptomatic ovarian cancer by measuring the activation of the immune system in blood samples in response to early stage ovarian tumor cell development.

In clinical development, OvaDx has indicated high sensitivity and specificity for all types and stages of ovarian cancer, including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous and ovarian adenocarcinoma. Upon FDA approval, Avant plans to offer its diagnostic product as an elective test for women seeking greater wellness, as well as those in the elevated risk category for ovarian cancer.

OvaDx is also expected to be used by doctors to advance the forefront of ovarian cancer treatment, promoting the utilization of improved surgical options and more effective chemotherapies by serving as a supplement to existing tests, such as CA-125, OVA1® and transvaginal ultrasound. In this way, Avant's innovative product will promote earlier diagnoses and, as a result, improved survival rates for patients with ovarian cancer.

As it continues to seek FDA approval for its groundbreaking diagnostic technology, Avant is poised to promote considerable growth in the ovarian cancer market, addressing what is currently the most deadly cancer of the female reproductive system. The company will lean on the industry experience of its management team in order to continue positioning itself for long-term success in the medical diagnostic market. Disclaimer

Avant Diagnostics, Inc. Company Blog

Avant Diagnostics, Inc. News:

Avant Diagnostics Inc. Receives FDA IRB Approval for OvaDx(R) Ovarian Cancer Validation Test Specimens

Avant Diagnostics Inc. Engages Goal Capital Inc. to Provide Investor Relations Services

Avant Diagnostics, Inc. Appoints Marcum LLP as Its New Independent Registered Public Accounting Firm


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



1-2-3 Stock Alerts





By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251